Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C18H27NO2.C2H6O6S2 |
Molecular Weight | 769.02 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)CCS(O)(=O)=O.CCN(CC)CCOC(=O)C1(CCCC1)C2=CC=CC=C2.CCN(CC)CCOC(=O)C3(CCCC3)C4=CC=CC=C4
InChI
InChIKey=BANIDACEBXZGNK-UHFFFAOYSA-N
InChI=1S/2C18H27NO2.C2H6O6S2/c2*1-3-19(4-2)14-15-21-17(20)18(12-8-9-13-18)16-10-6-5-7-11-16;3-9(4,5)1-2-10(6,7)8/h2*5-7,10-11H,3-4,8-9,12-15H2,1-2H3;1-2H2,(H,3,4,5)(H,6,7,8)
Caramiphen is a muscarinic M1 acetylcholine receptor antagonist, which was used for the treatment of Parkinson Disease and cough, but then there using were discontinued. Caramiphen is also used in local anesthesia, and effect could be achieved through the suppression of voltage-gated Na⁺ currents.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: voltage-gated Na⁺ currents Sources: https://www.ncbi.nlm.nih.gov/pubmed/25446426 |
52.1 µM [IC50] | ||
Target ID: P11229 Gene ID: 1128.0 Gene Symbol: CHRM1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8449241 |
1.2 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3322860 |
Primary | SKF TUSS-ORNADE Approved UseUnknown |
||
Primary | parpanit Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg single, oral |
healthy, adult n = 30 Health Status: healthy Condition: cough Age Group: adult Sex: unknown Population Size: 30 Sources: |
Other AEs: Nausea, Dizziness... Other AEs: Nausea (3 patients) Sources: Dizziness (2 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | 2 patients | 20 mg single, oral |
healthy, adult n = 30 Health Status: healthy Condition: cough Age Group: adult Sex: unknown Population Size: 30 Sources: |
Nausea | 3 patients | 20 mg single, oral |
healthy, adult n = 30 Health Status: healthy Condition: cough Age Group: adult Sex: unknown Population Size: 30 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Anti-nicotinic properties of anticholinergic antiparkinson drugs. | 1998 Nov |
|
Caramiphen and scopolamine prevent soman-induced brain damage and cognitive dysfunction. | 2002 May |
|
Anticholinergic and antiglutamatergic agents protect against soman-induced brain damage and cognitive dysfunction. | 2003 Sep |
|
Extrapolating from animal studies to the efficacy in humans of a pretreatment combination against organophosphate poisoning. | 2007 May |
|
Anticonvulsant efficacy of drugs with cholinergic and/or glutamatergic antagonism microinfused into area tempestas of rats exposed to soman. | 2008 Feb |
|
Efficacy of antidotal treatment against sarin poisoning: the superiority of benactyzine and caramiphen. | 2008 Feb 15 |
|
Antiparkinson drugs used as prophylactics for nerve agents: studies of cognitive side effects in rats. | 2008 Jun |
|
Therapy against organophosphate poisoning: the importance of anticholinergic drugs with antiglutamatergic properties. | 2008 Oct 15 |
|
Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment. | 2010 Dec |
|
Roles of perirhinal and posterior piriform cortices in control and generation of seizures: a microinfusion study in rats exposed to soman. | 2010 Jan |
|
Isobolographic analysis of caramiphen and lidocaine on spinal anesthesia in rats. | 2010 Jan 18 |
|
[Novel antidepressant-like action of drugs possessing GIRK channel blocking action in rats]. | 2010 May |
|
Antidepressant-like effect of centrally acting non-narcotic antitussive caramiphen in a forced swimming test. | 2010 Sep 13 |
|
The anticholinergic and antiglutamatergic drug caramiphen reduces seizure duration in soman-exposed rats: synergism with the benzodiazepine diazepam. | 2012 Mar 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://doi.org/10.1016/S0079-6468(08)70117-6
2.5 to 6.0 mg/kg
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25446426
It was investigated the effect of caramiphen (300uM) on voltage-gated sodium channels in differentiated neuronal NG108-15 cells. Caramiphen exhibited a milder state-dependence of block (IC₅₀ of 52.1 and 99.5 µM at holding potentials of -70 and -100 mV, respectively).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29698
Created by
admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
|
||
|
CFR |
21 CFR 520.301
Created by
admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C76459
Created by
admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
|
PRIMARY | |||
|
m3048
Created by
admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000084850
Created by
admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
|
PRIMARY | |||
|
DTXSID9047835
Created by
admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
|
PRIMARY | |||
|
517304
Created by
admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
|
PRIMARY | |||
|
DBSALT001670
Created by
admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
|
PRIMARY | |||
|
133053
Created by
admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
|
PRIMARY | RxNorm | ||
|
09TQU5PG95
Created by
admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
|
PRIMARY | |||
|
125-86-0
Created by
admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
|
PRIMARY | |||
|
SUB01036MIG
Created by
admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
|
PRIMARY | |||
|
204-759-0
Created by
admin on Fri Dec 15 15:05:00 GMT 2023 , Edited by admin on Fri Dec 15 15:05:00 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD